Isabel Kurth's Colleagues at Rgenix
Isabel Kurth's Contact Details
646-856-9261
Greater New York City Area
Rgenix
Isabel Kurth's Company Details
Inspirna (formerly Rgenix) is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Inspirna's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways.Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies.Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016.